Cooper Companies (NASDAQ:COO - Get Free Report) had its price target decreased by Citigroup from $115.00 to $110.00 in a research note issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the medical device company's stock. Citigroup's price target would indicate a potential upside of 35.75% from the stock's current price.
Several other analysts have also recently weighed in on COO. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research note on Friday. Morgan Stanley cut their target price on Cooper Companies from $104.00 to $102.00 and set an "equal weight" rating for the company in a research note on Friday, December 6th. Wells Fargo & Company upped their price target on Cooper Companies from $115.00 to $118.00 and gave the company an "overweight" rating in a research note on Friday, December 6th. Finally, StockNews.com downgraded Cooper Companies from a "buy" rating to a "hold" rating in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $111.89.
Check Out Our Latest Stock Report on Cooper Companies
Cooper Companies Price Performance
COO traded up $1.14 on Friday, hitting $81.03. 3,370,815 shares of the company's stock were exchanged, compared to its average volume of 1,725,305. Cooper Companies has a fifty-two week low of $78.43 and a fifty-two week high of $112.38. The stock has a market cap of $16.17 billion, a price-to-earnings ratio of 41.55, a P/E/G ratio of 2.25 and a beta of 1.02. The firm has a 50-day moving average price of $92.14 and a 200-day moving average price of $99.34. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32.
Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. As a group, equities analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current year.
Institutional Trading of Cooper Companies
Several hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. grew its holdings in shares of Cooper Companies by 23.0% in the third quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company's stock valued at $435,856,000 after purchasing an additional 737,726 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Cooper Companies in the fourth quarter worth $691,000. Highland Capital Management LLC purchased a new stake in shares of Cooper Companies during the fourth quarter worth $4,004,000. Caprock Group LLC acquired a new stake in shares of Cooper Companies in the fourth quarter valued at $282,000. Finally, Franklin Resources Inc. raised its stake in shares of Cooper Companies by 194.0% in the third quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company's stock valued at $5,265,000 after acquiring an additional 32,260 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company's stock.
About Cooper Companies
(
Get Free Report)
The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.
Featured Stories
Before you consider Cooper Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cooper Companies wasn't on the list.
While Cooper Companies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
